Navigation Links
ONCOTHYREON APPOINTS JULIE M. EASTLAND AS CHIEF FINANCIAL OFFICER
Date:8/31/2010

SEATTLE, Aug. 31 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced the appointment of Julie M. Eastland as Chief Financial Officer and Vice President, Corporate Development, effective September 7, 2010. Ms. Eastland's responsibilities will include financial management, investor relations and business development.

"Ms. Eastland brings more than 25 years of financial management experience to Oncothyreon," said Robert L. Kirkman, M.D., President and CEO of Oncothyreon. "We are confident that this experience, coupled with her strategic planning and operational expertise in the biotechnology arena, will be an asset to our company, and we welcome her to our management team."

"I am delighted to join Oncothyreon and am looking forward to contributing to the company's development," said Ms. Eastland. "With the first interim look for the START trial of Stimuvax expected by year end, and with multiple Phase 2 trials for the PI-3 kinase inhibitor PX-866 being planned, it is an exciting time in Oncothyreon's history."

Ms. Eastland served as Chief Financial Officer and Vice President Finance and Operations of VLST Corporation, a privately-held biotechnology company, from February 2006 to 2010. From 2000 to 2005, Ms. Eastland held various finance positions at Dendreon Corporation, a publicly-traded biotechnology company, most recently as the Vice President of Strategic Planning. Prior to Dendreon, Ms. Eastland worked for Amgen, Inc. as area finance manager and assistant controller for its Colorado operations. Ms. Eastland has also worked as director of finance and planning for Encore Media Group, international finance and business manager and senior financial analyst for SCIENCE Magazine and financial manager for the Discovery Channel. Ms. Eastland received an M.B.A. from Edinburgh University Management School and a B.S. in finance from Colorado State University.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit www.oncothyreon.com.

Forward-Looking Statements

This release contains statements that are forward-looking, including statements regarding Oncothyreon's expectations regarding clinical development activities. Although Oncothyreon believes that the forward-looking statements contained herein are reasonable, it can give no assurance that its expectations are correct. Forward-looking statements involve risks and uncertainties, many of which are beyond Oncothyreon's control. For a detailed description of such risks and uncertainties, you are encouraged to review the official corporate documents filed with the securities regulators in the United States on U.S. EDGAR and in Canada on SEDAR. Oncothyreon does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.


'/>"/>
SOURCE Oncothyreon Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Oncothyreon reports second quarter 2010 financial results
2. Oncothyreon announces second quarter 2010 financial results conference call
3. Oncothyreon announces presentations at upcoming investor conferences in June
4. Oncothyreon to present at the Rodman & Renshaw Annual Global Investment Conference
5. Oncothyreon reports full year and fourth quarter 2009 financial results
6. Oncothyreon reports first quarter 2010 financial results
7. Oncothyreon announces temporary suspension of Stimuvax clinical trials by Merck Serono
8. Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement
9. Oncothyreons PX-866 PI-3 kinase inhibitor named among Top 10 most promising oncology products for partnering by Windhover
10. Oncothyreon reports third quarter 2009 financial results & provides product pipeline update
11. Oncothyreon announces webcast of third quarter 2009 financial results conference call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2016)... (PRWEB) , ... April 27, 2016 , ... ... of Lewis Roca Rothgerber Christie LLP as an associate in the firm’s Intellectual ... and international electrical, mechanical and electromechanical patent applications. He has an electrical engineering ...
(Date:4/26/2016)... ... April 26, 2016 , ... The European Patent Office (EPO) ... of three finalists for the European Inventor Award 2016 in the category "Non-European countries." ... announced at a ceremony in Lisbon on June 9th. , The human capacity to ...
(Date:4/26/2016)... ... 2016 , ... Mr. Palmer created the RPO business for Ceridian and lead ... managed services contract in the U.S. intelligence community with The SI (a Lockheed Martin ... Younger, founder of Accolo. “We are growing and his experience guiding our expansion ...
(Date:4/26/2016)... ... ... BioFactura, Inc ., a biopharmaceutical research and manufacturing company, announced today the ... significant oversubscription of the original $1.5M target. The funds will be used to ... , Chief Executive Officer and President, Darryl Sampey founded BioFactura in 2004 ...
Breaking Biology Technology:
(Date:3/23/2016)... , March 23, 2016 ... erhöhter Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender ... das Unternehmen mit SpeechPro zusammenarbeitet, um erstmals ... Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im Rahmen ...
(Date:3/22/2016)... and SANDY, Utah , March ... operates the highest sample volume laboratory in ... and UNIConnect, leaders in clinical sequencing informatics and molecular ... of a project to establish the informatics infrastructure for ... NSO has been contracted by the Ontario Ministry ...
(Date:3/18/2016)... -- --> --> Competitive ... Unmanned Vehicles, Physical infrastructure and Perimeter Surveillance & Detection Systems ... security market and the continuing migration crisis in the ... has led visiongain to publish this unique report, which ... defence & security companies in the border security market ...
Breaking Biology News(10 mins):